The master manager of big data talks about the new concept of big data for medicine
In recent years, the big data industry has become more active, and there is growing recognition of the importance of big data in promoting industrial innovation and social development. In the area of health care, although innovative initiatives have continued on the internet, their value has not yet been truly exploited due to technical bottlenecks in the collection and analysis of pharmaceutical data and insufficient awareness of their significance. “the big data on pharmaceuticals will not only be used by a large number of drug companies to help them understand the end markets and match production and sales, but will also serve society as a whole — to improve the health-care environment in a comprehensive manner and to help with drug safety.” corygao, managing director of big data on clouds, indicates。
“traditional pharmaceutical enterprises typically use manual management models to produce statistics of pharmaceutical data, starting at the level of second- and third-tier distributors, collecting, auditing and archiving, which are not only time-consuming, but also prone to errors, often some weeks or months ago. The time lag and low accuracy in data collection have resulted in production and supply imbalances, market positioning errors, which affect the decision-making and operation of manufacturers and may even cause the delivery of certain medicines to be cut off, thereby delaying the patient's condition.” according to mr. Song, head of the market for a pharmaceutical company in the country。
The pharmaceutical giant data provide an advanced concept and solution for enterprises to collect, integrate, refine, analyse, and help enterprises make accurate first-time judgements about the flow of their products to inventories through cross-sectional distributors, end-flow data and direct linkages to them, increase input output ratios, reduce production-to-market demand discrepancies and achieve information management across the marketing system. At the same time, data mining and information-gathering techniques can provide researchers with sufficient sample size and data information, establish mathematical models based on large data and predict future markets, thus exploiting market potential, promoting the development of new medicines, stimulating changes in the production industry and opening up new development opportunities for pharmaceutical companies。
“there are few companies in the country that really have access to the big data technology for pharmaceuticals, and we have met with some of the general directors of pharmaceutical companies, who find it very difficult to process, dock, analyse, and even think that it is impossible in the field of medicine. But we have made that impossible possible. Big cloud data, with more than five years of experience in medical data collection and processing and analysis, have provided smart channel management solutions to more than 20 well-known pharmaceutical companies, including several transnational giants. At the same time, we have a highly automated cloud platform, a standardized primary database that allows real-time data collection delivery. It can be said that cloud technology is also very advanced throughout south-east asia, and that it also sets the bar for domestic pharmaceutical data.” corygao is very proud to say: “we want to use the power of data to help business and, more importantly, to make a positive contribution to society as a whole and to national health.”
Today, as a result of uneven distribution of health-care resources, front-line cities are the first choice for many patients. The triple hospitals in the major cities of beijing and shanghai are almost “full” every day. According to the watching news weekly in may 2014, almost 220 million visits per year are made in beijing alone, averaging 700,000 field patients per day. These phenomena can only be explained by the high concentration of state-of-the-art technology and high-level doctors, as well as the latest and best available medicines, in major hospitals in front-line cities. Large pharmaceutical data help to alleviate this phenomenon. “we can use data to accurately capture the end-flow of medicines, to meet the needs of markets at all levels in a timely manner, to link up with the main databases of municipal district and even community hospitals, and in the future to help establish standards for the medical profession and reduce the rate of error. Corygao adds: “data is derived from and for the benefit of the people, and ultimately has a very positive impact on social stability and the promotion of national health.”
At present, there are about 4,000 state-owned, joint-venture and private pharmaceutical companies with strong production capacity in china; they are well known about the system of approval, invest considerable money in markets and sales, but they are locked in data. In contrast, china’s largest drug company now invests less than 1 million yuan a year in pharmaceutical data, while the same size of european and american drug companies invest 10 times more. The importance attached to data resources will greatly affect the research and development capacity, marketing capacity and development potential of pharmaceutical enterprises. Large data on health, on the other hand, will deepen development in the health sector as a whole and catalyse a new industrial revolution with far-reaching implications and broad development space。
Responsible editor: zhang dei
